03 May 2023
24 April 2023
19 April 2023
05 June 2023
Areas of focus
...
-
18 November 2024
-
18 November 2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III ope...
-
05 June 2023
-
05 June 2023
-
31 January 2024
- 4 mins read
-
31 January 2024
- 4 mins read
Closing Gaps in Cancer Care – Together
Dr. Mónica de Abadal, Head of Medical Affairs, North America at Ipsen shares why she believes it takes everyone in the healthcare ecosystem coming together to close existing gaps and address health inequities in cancer care. ...
-
05 June 2023
-
05 June 2023
Grant Requests
...
-
13 April 2023
-
13 April 2023
Home
...
-
30 June 2023
-
30 June 2023
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
PARIS, FRANCE, 30 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigat...